{"id":"vehicle-to-bimatoprost-solution","safety":{"commonSideEffects":[{"rate":"25-40","effect":"Conjunctival hyperemia"},{"rate":"10-20","effect":"Iris pigmentation increase"},{"rate":"10-15","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5-15","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Foreign body sensation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bimatoprost binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, enhancing drainage of aqueous humor through the uveoscleral (unconventional) pathway. This mechanism reduces intraocular pressure, which is the primary pathogenic factor in glaucoma and ocular hypertension. The vehicle formulation optimizes drug delivery and stability for topical ophthalmic administration.","oneSentence":"Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:06.418Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT04499248","phase":"PHASE1, PHASE2","title":"AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-11-16","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":96},{"nctId":"NCT01391273","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-07-01","conditions":"Eyelash Hypotrichosis","enrollment":173},{"nctId":"NCT01391286","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-07-01","conditions":"Eyelash Hypotrichosis","enrollment":36},{"nctId":"NCT01765764","phase":"PHASE3","title":"Bimatoprost for the Treatment of Eyebrow Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-03-13","conditions":"Eyebrow Hypotrichosis","enrollment":357},{"nctId":"NCT01023841","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Eyelash Hypotrichosis, Alopecia Areata","enrollment":71},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT01698554","phase":"PHASE3","title":"Bimatoprost in the Treatment of Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-11","conditions":"Idiopathic Eyelash Hypotrichosis","enrollment":464},{"nctId":"NCT02170662","phase":"PHASE2","title":"Topical Bimatoprost Effect on Androgen Dependent Hair Follicles","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-11","conditions":"Male Pattern Hair Loss, Androgenetic Alopecia","enrollment":33},{"nctId":"NCT00693420","phase":"PHASE3","title":"Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-04","conditions":"Eyelashes","enrollment":278},{"nctId":"NCT01448525","phase":"PHASE4","title":"Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10","conditions":"Hypotrichosis","enrollment":88},{"nctId":"NCT00907426","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-08","conditions":"Hypotrichosis","enrollment":368}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vehicle to bimatoprost solution","genericName":"Vehicle to bimatoprost solution","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}